Study of Lisaftoclax plus azacitidine for new AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new pill (APG-2575, also called Lisaftoclax) combined with a standard injection (azacitidine) for adults with newly diagnosed AML who cannot take strong chemotherapy. The goal is to see if this combination works better than treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with acute myeloid leukemia (AML) and cannot receive standard chemotherapy.
- Your doctor expects you to live at least 3 more months.
- You are able to take pills by mouth.
- If you are 70 or older, you are reasonably active (ECOG score 0-2). If you are 18-69, you may be less active (ECOG score 0-3).
- Your kidneys and liver are working well enough, and your white blood cell count is not too high (30,000 or less).
- You have not had treatment for a blood disorder before, and you do not have certain other cancers or heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
This trial tests a new drug called AK117 combined with two standard AML medicines (azacitidine and venetoclax) for people with acute myeloid leukemia who haven't had certain prior treatments. The goal is to see if this combination works better and is safe.
This trial tests a new drug, lisaftoclax, combined with azacytidine for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this combination can help control the disease better.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.